Optimising Solubility: Selecting The Right Technology For Early Drug Development

Poor aqueous solubility is one of the most common obstacles facing modern drug candidates, often leading to low or variable oral absorption if not addressed early. A wide range of formulation technologies can improve solubility or dissolution rate, but each comes with trade‑offs that must be weighed against the molecule’s physicochemical properties, dose requirements, and development stage. In early development, priorities typically include achieving high exposure for toxicology studies, enabling flexible dosing in first‑in‑human trials, and minimizing manufacturing complexity. Liquid formulations are therefore often favored, whether as nanosuspensions, lipid‑based systems, cosolvent solutions, cyclodextrin complexes, or suspensions of amorphous solid dispersions. Each approach offers distinct advantages and limitations in terms of payload, stability, precipitation risk, and scalability. Thoughtful technology selection helps balance performance with practicality while avoiding unnecessary complexity. By aligning solubility strategy with early clinical and preclinical needs, development teams can reduce risk, improve translatability, and create a smoother path toward later‑stage solid dosage form development.